Latest:
Dr. Naidoo Discusses Biomarker Testing for Checkpoint Inhibitors
Jarushka Naidoo, MD, BCh, discusses the application of biomarker testing for use of checkpoint inhibitors in patients with cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jasmeet C. Singh, MD
Latest:
Dr. Singh on Dose Dense ACTHP in HER2+ Breast Cancer
Jasmeet C. Singh, MD, discusses results from a retrospective analysis looking at the effectiveness of dose dense doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer.
Jasmine M. Zain, MD
Latest:
Dr. Zain on Targets Under Investigation in T-Cell Lymphomas
Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses targets that are under investigation in T-cell lymphomas.
Jasmine Rassiwala, MD
Latest:
Dr. Rassiwala on Results of "All-comers" Downstaging Protocol
Jasmine Rassiwala, MD, resident physician, University of California, San Francisco, discusses the analysis of the “all-comers” downstaging protocol, which investigated whether there were upper limits in tumor burden for successful downstaging of patients with hepatocellular carcinoma to liver transplant.
Jason D. Wright, MD
Latest:
Dr. Wright on Measuring Progression and Recurrence in Ovarian Cancer
Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the challenges in measuring progression and recurrence in patients with ovarian cancer.
Jason E. Sandler, MD
Latest:
Early-Stage NSCLC Is Ripe for Change
Following a 2-decade lull in early-stage lung cancer, we are now seeing much better-designed neoadjuvant and adjuvant studies based on proper biomarker selection, as well as optimized treatment choices founded upon recent advances in the metastatic setting.
Jason Harris
Senior Editor,
Latest:
Adding Patient-Specific Comorbidities May Improve Risk Evaluation in Myelofibrosis
Adding patient-specific comorbidities improved the prognostic effect of risk prediction models for patients with primary or secondary myelofibrosis, according to findings from an assessment of data collected in Vanderbilt’s Synthetic Derivative and BioVU Biobank comprehensive electronic health record.
Jason J. Luke, MD
Latest:
Dr Luke on Results of KEYNOTE-716 of Adjuvant Pembrolizumab in Stage IIB/C Melanoma
Jason Luke, MD, FACP, discusses the final analysis of distant metastasis–free survival in the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma.
Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center
Latest:
Dr Luke on the Background of the KEYNOTE-716 Trial in High-Risk Melanoma
Jason Luke, MD, FACP, discusses the background of the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma, highlighting previous data from the trial that led to the 36-month follow-up report.